IVBXF Stock Chart & Stats
$14.20
-$1.97(-15.39%)
At close: 4:00 PM EDT
$14.20
-$1.97(-15.39%)
Day’s Range― - ―
52-Week Range$9.07 - $15.01
Previous CloseN/A
Volume539.00
Average Volume (3M)1.78K
Market Cap
$20.80B
Enterprise Value$122.92K
Total Cash (Recent Filing)$20.00B
Total Debt (Recent Filing)$2.32B
Price to Earnings (P/E)112.8
Beta-0.06
Next Earnings
Mar 31, 2027EPS Estimate
0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.71
Shares Outstanding1,743,864,600
10 Day Avg. Volume1,602
30 Day Avg. Volume1,783
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)6.12
Price to Sales (P/S)9.09
P/FCF Ratio12.72
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$17.01Price Target Upside19.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)0.17
Revenue Forecast (FY)$2.38B
Bulls Say, Bears Say
Bulls Say
Revenue And Profit InflectionThe 2025 increase in revenue and return to positive net income indicate stronger commercial execution and improving operating scale. If sustained, this inflection can provide more internal funding for the pipeline, support broader commercialization, and strengthen the company’s earnings base over the next several quarters.
Strong Gross ProfitabilityThe sharp improvement in gross margin demonstrates strong economics on the company’s commercial biologic products and suggests greater value capture as revenue expands. A high gross-profit base gives Innovent room to fund research, sales infrastructure, and regulatory activity while still progressing toward stronger net profitability.
Conservative Balance SheetLow leverage and a substantially larger equity base provide financial flexibility for a research-intensive biopharmaceutical business. This capital position can help Innovent continue clinical development and commercialization without the same debt burden as a more highly leveraged peer, supporting resilience through investment cycles.
Bears Say
Unproven Profitability DurabilityThe recent profit turnaround is meaningful, but the preceding multi-year period of operating losses shows that sustainable earnings have not yet been established. Continued profitability will depend on maintaining product growth and controlling operating costs, leaving execution risk material over the next several quarters.
Uneven Cash-flow HistoryThe strong 2025 cash generation is encouraging, yet the preceding history shows substantial inconsistency in converting operations into cash. This raises the possibility that the latest improvement includes timing or non-recurring effects, making future funding capacity and investment planning less predictable until the trend is repeated.
Modest Net ProfitabilityPositive earnings have returned, but the relatively modest net margin and low return level indicate that revenue growth has not yet translated into robust overall profitability. Limited bottom-line conversion could constrain reinvestment capacity and leave results sensitive to development spending and commercialization costs.
Innovent Biologics News
IVBXF FAQ
What was Innovent Biologics’s price range in the past 12 months?
Innovent Biologics lowest stock price was $9.07 and its highest was $15.01 in the past 12 months.
What is Innovent Biologics’s market cap?
Innovent Biologics’s market cap is $20.80B.
When is Innovent Biologics’s upcoming earnings report date?
Innovent Biologics’s upcoming earnings report date is Mar 31, 2027 which is in 198 days.
How were Innovent Biologics’s earnings last quarter?
Innovent Biologics released its earnings results on Aug 25, 2026. The company reported $0.104 earnings per share for the quarter, beating the consensus estimate of $0.07 by $0.034.
Is Innovent Biologics overvalued?
According to Wall Street analysts Innovent Biologics’s price is currently Undervalued.
Does Innovent Biologics pay dividends?
Innovent Biologics does not currently pay dividends.
What is Innovent Biologics’s EPS estimate?
Innovent Biologics’s EPS estimate is 0.17.
How many shares outstanding does Innovent Biologics have?
Innovent Biologics has 1,743,864,600 shares outstanding.
What happened to Innovent Biologics’s price movement after its last earnings report?
Innovent Biologics reported an EPS of $0.104 in its last earnings report, beating expectations of $0.07. Following the earnings report the stock price went down -2.278%.
Which hedge fund is a major shareholder of Innovent Biologics?
Currently, no hedge funds are holding shares in IVBXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innovent Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.01 (19.78% Upside)
$17.01 (19.78% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
86.27%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Innovent Biologics
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
IVBXF Stock 12 Month Forecast
Average Price Target
$17.01
▲(19.78% Upside)
Technical Analysis
3SBio
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―
Ownership Overview
―
Insiders
8.81% Mutual Funds
― Other Institutional Investors
81.86% Public Companies and
Individual Investors